Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$739.07

44 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $739.07 44

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1922027853?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

44 matching records · $739.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 44 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–44 of 44.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $20.0612/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747825805 CMS
Merck Sharp & Dohme Corporation $14.9712/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747816347 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.7811/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720532599 CMS
Novo Nordisk Inc $18.6311/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745002455 CMS
Novo Nordisk Inc $18.5410/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744934879 CMS
Teva Pharmaceuticals USA, Inc. $13.8410/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749555743 CMS
Lilly USA, LLC $16.4109/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728363891 CMS
Novo Nordisk Inc $16.2909/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744919443 CMS
PFIZER INC. $14.7409/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743351519 CMS
Merck Sharp & Dohme Corporation $16.6808/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747641059 CMS
Allergan, Inc. $13.1008/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723491217 CMS
GlaxoSmithKline, LLC. $11.0208/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738558375 CMS
AstraZeneca Pharmaceuticals LP $12.2808/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736092015 CMS
Lilly USA, LLC $16.1808/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728370683 CMS
Lilly USA, LLC $16.0607/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728363889 CMS
Lilly USA, LLC $13.9607/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728380899 CMS
Novo Nordisk Inc $19.3007/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744797455 CMS
AstraZeneca Pharmaceuticals LP $13.9007/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735791755 CMS
AstraZeneca Pharmaceuticals LP $11.5306/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736103363 CMS
Astellas Pharma US Inc $15.0606/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718372137 CMS
Amarin Pharma Inc. $23.8006/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739824503 CMS
Novo Nordisk Inc $15.3706/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744760259 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8405/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720988345 CMS
Allergan, Inc. $20.5205/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723491215 CMS
AstraZeneca Pharmaceuticals LP $13.4305/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736217925 CMS
Allergan, Inc. $22.8804/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723491213 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.9204/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720532605 CMS
PFIZER INC. $15.1103/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743146199 CMS
GlaxoSmithKline, LLC. $11.7903/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738887917 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7202/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747286455 CMS
Amarin Pharma Inc. $23.5902/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739824515 CMS
Antares Pharma, Inc. $14.3102/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751419173 CMS
Astellas Pharma US Inc $14.7702/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718372135 CMS
Novo Nordisk Inc $14.5102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744736007 CMS
Allergan, Inc. $15.3802/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723491211 CMS
PFIZER INC. $12.5502/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743655795 CMS
Cardiovascular Systems Inc. $20.7802/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751967855 CMS
GlaxoSmithKline, LLC. $14.8301/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738556799 CMS
Merck Sharp & Dohme Corporation $9.4201/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747651541 CMS
AstraZeneca Pharmaceuticals LP $49.6201/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736451377 CMS
Astellas Pharma US Inc $19.6601/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718372133 CMS
Astellas Pharma US Inc $20.9201/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718372131 CMS
AstraZeneca Pharmaceuticals LP $11.8101/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736169313 CMS
Lilly USA, LLC $11.2101/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728370681 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

648 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Horizon Therapeutics plc $23,845.00 12/31/2020 Non-covered Recipient Entity
AVAIL RESEARCH
A MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA? (PEGLOTICASE) (MIRROR [OL]) No dispute reported 06/30/2026 723128113
Principal investigator 1 PFIZER INC. $3,627.48 12/29/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742894697
Principal investigator 1 Janssen Research & Development, LLC $84,100.00 12/22/2020 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719529767
Principal investigator 1 Janssen Research & Development, LLC $14,405.00 12/22/2020 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719529769
Principal investigator 1 Janssen Research & Development, LLC $14,405.00 12/22/2020 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719529771
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205557
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205559
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205561
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205563
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205565
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205567
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205569
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205571
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205573
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205575
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205577
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205579
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205581
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205583
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205585
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205587
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205589
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205591
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205593
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205595
Principal investigator 1 Emergent BioSolutions Inc. $226.09 12/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205597
Principal investigator 1 PFIZER INC. $3,580.23 12/19/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742894427
Principal investigator 1 PFIZER INC. $50.00 12/17/2020 Non-covered Recipient Entity
University Clinical ResearchDeLand dba Accel Research Sites
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742894559
Principal investigator 1 PFIZER INC. $7,367.75 12/16/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742894555
Principal investigator 1 PFIZER INC. $8,918.84 12/12/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742894429
Principal investigator 1 PFIZER INC. $13,411.01 12/05/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742894425
Principal investigator 1 PFIZER INC. $1,950.00 12/03/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742894693
Principal investigator 1 PFIZER INC. $268.75 12/02/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742894699
Principal investigator 1 PFIZER INC. $20,104.35 11/28/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915599
Principal investigator 1 PFIZER INC. $27,595.56 11/21/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915865
Principal investigator 1 PFIZER INC. $3,140.80 11/21/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742921043
Principal investigator 1 PFIZER INC. $1,300.00 11/21/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742922316
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205483
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205485
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205487
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205489
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205491
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205493
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205495
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205497
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205499
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205501
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205503
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205505
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205507
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205509
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205511
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205513
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205515
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205517
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205519
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205521
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205523
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205525
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205527
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205529
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205531
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205533
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205535
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205537
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205539
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205541
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205543
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205545
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205547
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205549
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205551
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205553
Principal investigator 1 Emergent BioSolutions Inc. $226.09 11/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205555
Principal investigator 1 PFIZER INC. $41,904.48 11/18/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742921117
Principal investigator 1 PFIZER INC. $35.00 11/18/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742921121
Principal investigator 1 PFIZER INC. $41,076.09 11/17/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915603
Recipient GlaxoSmithKline, LLC. $3,500.00 11/11/2020 Covered Recipient Physician MENB REC 2ND GEN-045 (V72_79) No dispute reported 06/30/2026 753909581
Recipient GlaxoSmithKline, LLC. $1,500.00 11/11/2020 Covered Recipient Physician MENB REC 2ND GEN-045 (V72_79) No dispute reported 06/30/2026 753910181
Principal investigator 1 PFIZER INC. $35.00 11/11/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742921037
Principal investigator 1 PFIZER INC. $61,272.83 11/07/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915993
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $11,460.00 11/03/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 749682547
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $650.00 11/03/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 749683695
Principal investigator 1 Emergent BioSolutions Inc. $3,811.09 11/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205481
Principal investigator 1 PFIZER INC. $59,208.03 10/31/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915955
Principal investigator 1 PFIZER INC. $301.00 10/30/2020 Non-covered Recipient Entity
University Clinical ResearchDeLand dba Accel Research Sites
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742921371
Principal investigator 1 PFIZER INC. $3,511.30 10/29/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742921045
Principal investigator 1 PFIZER INC. $1,300.00 10/29/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742921123
Principal investigator 1 PFIZER INC. $65,176.60 10/23/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915863
Principal investigator 1 Emergent BioSolutions Inc. $226.09 10/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205471
Principal investigator 1 Emergent BioSolutions Inc. $226.09 10/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205473
Principal investigator 1 Emergent BioSolutions Inc. $226.09 10/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205475
Principal investigator 1 Emergent BioSolutions Inc. $226.09 10/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205477
Principal investigator 1 Emergent BioSolutions Inc. $226.09 10/21/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205479
Principal investigator 1 AbbVie Inc. $250.00 10/20/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
M19-974 No dispute reported 06/30/2026 721191485
Principal investigator 1 GlaxoSmithKline, LLC. $4,627.00 10/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 734923659
Principal investigator 1 PFIZER INC. $150,167.90 10/20/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915951
Principal investigator 1 PFIZER INC. $3,771.30 10/17/2020 Non-covered Recipient Entity
University Clinical ResearchDeLand dba Accel Research Sites
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742920981
Principal investigator 1 PFIZER INC. $5,850.00 10/17/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742922029
Principal investigator 1 PFIZER INC. $148,819.98 10/10/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915869
Principal investigator 1 PFIZER INC. $5,657.60 10/09/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742921039
Principal investigator 1 AstraZeneca UK Limited $13,056.69 10/08/2020 Non-covered Recipient Entity
University Clinical Research Llc
A single dose, non-randomized, open-label, parallel group study to assess the pharmacokinetics, safety and tolerability of AZD9977 in participants with renal impairment No dispute reported 06/30/2026 736738989
Principal investigator 1 PFIZER INC. $181,116.19 10/02/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915949
Principal investigator 1 PFIZER INC. $2,600.00 10/01/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742922031
Principal investigator 1 PFIZER INC. $233,091.02 09/26/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944383
Recipient Eli Lilly and Company $3,500.00 09/24/2020 Covered Recipient Physician PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 728717439
Principal investigator 1 PFIZER INC. $8,290.10 09/24/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742921049
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205413
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205415
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205417
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205419
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205421
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205423
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205425
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205427
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205429
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205431
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205433
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205435
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205437
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205439
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205441
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205443
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205445
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205447
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205449
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205451
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205453
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205455
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205457
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205459
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205461
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205463
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205465
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205467
Principal investigator 1 Emergent BioSolutions Inc. $226.09 09/22/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205469
Principal investigator 1 PFIZER INC. $10,465.00 09/19/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742922319
Principal investigator 1 PFIZER INC. $243,790.38 09/19/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944325
Principal investigator 1 PFIZER INC. $3,057.00 09/18/2020 Non-covered Recipient Entity
University Clinical ResearchDeLand dba Accel Research Sites
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742920841
Principal investigator 1 PFIZER INC. $195,589.20 09/12/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944387
Principal investigator 1 PFIZER INC. $302,635.14 09/10/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742943945
Principal investigator 1 AbbVie Inc. $1,746.10 09/08/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
M19-974 No dispute reported 06/30/2026 721185417
Principal investigator 1 PFIZER INC. $17,035.20 09/03/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920833
Principal investigator 1 PFIZER INC. $896.48 09/03/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920837
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $4,514.85 09/01/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 749677781
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,100.00 09/01/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 749684901
Principal investigator 1 PFIZER INC. $182,697.96 08/29/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944357
Principal investigator 1 GlaxoSmithKline, LLC. $2,242.00 08/25/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 734909549
Principal investigator 1 PFIZER INC. $93,532.92 08/22/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944355
Principal investigator 1 PFIZER INC. $175.00 08/20/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742921127
Principal investigator 1 PFIZER INC. $750.00 08/20/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742921129
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205399
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205401
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205403
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205405
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205407
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205409
Principal investigator 1 Emergent BioSolutions Inc. $226.09 08/19/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205411
Principal investigator 1 PFIZER INC. $3,900.00 08/19/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944201
Principal investigator 1 PFIZER INC. $391,492.72 08/18/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944323
Principal investigator 1 SANOFI PASTEUR INC. $6.50 08/13/2020 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744031533
Principal investigator 1 Emergent BioSolutions Inc. $1,373.59 08/04/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205397
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $16,456.50 08/04/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
C3718-301 No dispute reported 06/30/2026 749679049
Principal investigator 1 PFIZER INC. $2,600.00 08/01/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742943883
Recipient Eli Lilly and Company $2,102.17 07/28/2020 Covered Recipient Physician A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 728717627
Principal investigator 1 PFIZER INC. $298.28 07/23/2020 Non-covered Recipient Entity
Avail Clinical Research LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742921603
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205351
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205353
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205355
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205357
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205359
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205361
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205363
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205365
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205367
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205369
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205371
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205373
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205375
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205377
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205379
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205381
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205383
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205385
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205387
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205389
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205391
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205393
Principal investigator 1 Emergent BioSolutions Inc. $226.09 07/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205395
Principal investigator 1 PFIZER INC. $7,507.50 07/17/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742943941
Principal investigator 1 Ferring Pharmaceuticals AS $4,604.80 07/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721460085
Principal investigator 1 American Regent $1,000.00 07/08/2020 Non-covered Recipient Entity
University Clinical Rsearch - Deland, Llc
Heart_FID No dispute reported 06/30/2026 737107025
Principal investigator 1 PFIZER INC. $65.00 07/08/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742921033
Principal investigator 1 GlaxoSmithKline, LLC. $1,699.20 07/07/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 734909547
Principal investigator 1 PFIZER INC. $4,473.70 07/02/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742943579
Principal investigator 1 PFIZER INC. $2,470.00 07/02/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742943881
Principal investigator 1 PFIZER INC. $120.35 06/26/2020 Non-covered Recipient Entity
Avail Clinical
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742954791
Principal investigator 1 PFIZER INC. $750.00 06/24/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942254
Principal investigator 1 Emergent BioSolutions Inc. $3,811.09 06/23/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205349
Principal investigator 1 PFIZER INC. $12,597.00 06/16/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742943877
Principal investigator 1 PFIZER INC. $871.82 06/11/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742942209
Principal investigator 1 PFIZER INC. $17,609.57 06/11/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742942251
Principal investigator 1 Emergent BioSolutions Inc. $171.09 06/09/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205347
Principal investigator 1 PFIZER INC. $7,000.00 06/05/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944351
Principal investigator 1 PFIZER INC. $13,510.06 06/04/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942249
Principal investigator 1 PFIZER INC. $2,249.26 06/04/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954785
Principal investigator 1 GlaxoSmithKline, LLC. $6,503.84 06/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 734912005
Principal investigator 1 PFIZER INC. $8,027.50 05/29/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742961881
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 05/26/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745301
Principal investigator 1 PFIZER INC. $144.00 05/20/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954753
Principal investigator 1 PFIZER INC. $8,151.00 05/15/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742962959
Principal investigator 1 Merck Sharp & Dohme Corporation $1,363.20 05/14/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745303
Principal investigator 1 PFIZER INC. $4,480.97 05/09/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937073
Principal investigator 1 AbbVie Inc. $3,500.00 05/07/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
M19-974 No dispute reported 06/30/2026 721165595
Principal investigator 1 PFIZER INC. $9,231.35 05/02/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742961885
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 05/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND
A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF DAPRODUSTAT O No dispute reported 06/30/2026 734909207
Principal investigator 1 PFIZER INC. $2,450.71 05/01/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742954825
Principal investigator 1 PFIZER INC. $1,482.00 04/30/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742962659
Principal investigator 1 PFIZER INC. $489.76 04/30/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742969009
Principal investigator 1 AbbVie Inc. $10,000.00 04/22/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
M19-974 No dispute reported 06/30/2026 721161729
Principal investigator 1 PFIZER INC. $500.00 04/21/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742934403
Principal investigator 1 PFIZER INC. $26,305.50 04/21/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742962581
Principal investigator 1 PFIZER INC. $2,712.25 04/14/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954789
Principal investigator 1 American Regent $1,750.00 04/08/2020 Non-covered Recipient Entity
University Clinical Rsearch - Deland, Llc
Heart_FID No dispute reported 06/30/2026 737106613
Principal investigator 1 PFIZER INC. $118.00 04/07/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954756
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205245
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205247
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205249
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205251
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205253
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205255
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205257
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205259
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205261
Principal investigator 1 Emergent BioSolutions Inc. $1,092.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205263
Principal investigator 1 Emergent BioSolutions Inc. $1,092.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205265
Principal investigator 1 Emergent BioSolutions Inc. $1,092.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205267
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205269
Principal investigator 1 Emergent BioSolutions Inc. $890.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205271
Principal investigator 1 Emergent BioSolutions Inc. $890.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205273
Principal investigator 1 Emergent BioSolutions Inc. $813.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205275
Principal investigator 1 Emergent BioSolutions Inc. $798.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205277
Principal investigator 1 Emergent BioSolutions Inc. $798.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205279
Principal investigator 1 Emergent BioSolutions Inc. $664.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205281
Principal investigator 1 Emergent BioSolutions Inc. $664.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205283
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205285
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205287
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205289
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205291
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205293
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205295
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205297
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205299
Principal investigator 1 Emergent BioSolutions Inc. $599.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205301
Principal investigator 1 Emergent BioSolutions Inc. $483.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205303
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205305
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205307
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205309
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205311
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205313
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205315
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205317
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205319
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205321
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205323
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205325
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205327
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205329
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205331
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205333
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205335
Principal investigator 1 Emergent BioSolutions Inc. $226.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205337
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205339
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205341
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205343
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 04/01/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205345
Principal investigator 1 Merck Sharp & Dohme Corporation $1,363.20 03/24/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745305
Principal investigator 1 PFIZER INC. $4,199.00 03/19/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742962961
Principal investigator 1 Ferring Pharmaceuticals AS $1,500.00 03/18/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459705
Principal investigator 1 Emergent BioSolutions Inc. $733.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205175
Principal investigator 1 Emergent BioSolutions Inc. $2,023.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205177
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205179
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205181
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205183
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205185
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205187
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205189
Principal investigator 1 Emergent BioSolutions Inc. $599.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205191
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205193
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205195
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205197
Principal investigator 1 Emergent BioSolutions Inc. $1,943.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205199
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205201
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205203
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205205
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205207
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205209
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205211
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205213
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205215
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205217
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205219
Principal investigator 1 Emergent BioSolutions Inc. $1,918.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205221
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205223
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205225
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205227
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205229
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205231
Principal investigator 1 Emergent BioSolutions Inc. $1,918.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205233
Principal investigator 1 Emergent BioSolutions Inc. $890.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205235
Principal investigator 1 Emergent BioSolutions Inc. $890.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205237
Principal investigator 1 Emergent BioSolutions Inc. $890.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205239
Principal investigator 1 Emergent BioSolutions Inc. $890.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205241
Principal investigator 1 Emergent BioSolutions Inc. $813.09 03/16/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205243
Principal investigator 1 Horizon Therapeutics plc $5,000.00 03/11/2020 Non-covered Recipient Entity
AVAIL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA? (PEGLOTICASE) (MIRROR RANDOMIZED CONTROLLED TRIAL [RCT]) No dispute reported 06/30/2026 723909335
Principal investigator 1 SANOFI PASTEUR INC. $15,600.00 03/05/2020 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744031451
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 03/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205163
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 03/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205165
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 03/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205167
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205169
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205171
Principal investigator 1 Emergent BioSolutions Inc. $226.09 03/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205173
Principal investigator 1 PFIZER INC. $1,216.48 02/28/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742968959
Principal investigator 1 PFIZER INC. $7,965.75 02/28/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978763
Principal investigator 1 PFIZER INC. $1,419.50 02/26/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742969011
Principal investigator 1 PFIZER INC. $1,294.28 02/25/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742968955
Principal investigator 1 PFIZER INC. $857.50 02/25/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742978745
Principal investigator 1 Eli Lilly and Company $1,836.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728752715
Principal investigator 1 PFIZER INC. $7,039.50 02/21/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978765
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205071
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205073
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205075
Principal investigator 1 Emergent BioSolutions Inc. $1,092.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205077
Principal investigator 1 Emergent BioSolutions Inc. $1,092.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205079
Principal investigator 1 Emergent BioSolutions Inc. $1,070.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205081
Principal investigator 1 Emergent BioSolutions Inc. $664.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205083
Principal investigator 1 Emergent BioSolutions Inc. $664.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205085
Principal investigator 1 Emergent BioSolutions Inc. $664.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205087
Principal investigator 1 Emergent BioSolutions Inc. $599.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205089
Principal investigator 1 Emergent BioSolutions Inc. $599.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205091
Principal investigator 1 Emergent BioSolutions Inc. $599.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205093
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205095
Principal investigator 1 Emergent BioSolutions Inc. $599.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205097
Principal investigator 1 Emergent BioSolutions Inc. $599.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205099
Principal investigator 1 Emergent BioSolutions Inc. $483.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205101
Principal investigator 1 Emergent BioSolutions Inc. $483.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205103
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205105
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205107
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205109
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205111
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205113
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205115
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205117
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205119
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205121
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205123
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205125
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205127
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205129
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205131
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205133
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205135
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205137
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205139
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205141
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205143
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205145
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205147
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205149
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205151
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205153
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205155
Principal investigator 1 Emergent BioSolutions Inc. $1,252.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205157
Principal investigator 1 Emergent BioSolutions Inc. $1,155.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205159
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/20/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205161
Principal investigator 1 PFIZER INC. $500.00 02/20/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742934151
Principal investigator 1 PFIZER INC. $17,405.19 02/20/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742972779
Principal investigator 1 Merck Sharp & Dohme Corporation $3,237.60 02/18/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745347
Principal investigator 1 PFIZER INC. $3,348.00 02/13/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742972713
Principal investigator 1 PFIZER INC. $2,232.00 02/13/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742972719
Principal investigator 1 PFIZER INC. $1,086.50 02/13/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742972723
Principal investigator 1 PFIZER INC. $219.00 02/13/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742972787
Principal investigator 1 Eli Lilly and Company $13,281.68 02/11/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
EVALUATION OF THE EFFECT OF MIRIKIZUMAB ON THE PHARMACOKINETICS OF CYTOCHROME P450 SUBSTRATES IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728751191
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42,607.56 02/10/2020 Non-covered Recipient Entity
University Clinical Research
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod No dispute reported 06/30/2026 736763463
Principal investigator 1 Merck Sharp & Dohme Corporation $170.40 02/06/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745307
Principal investigator 1 Merck Sharp & Dohme Corporation $340.80 02/06/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745349
Principal investigator 1 Eli Lilly and Company $2,035.80 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728751197
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204929
Principal investigator 1 Emergent BioSolutions Inc. $1,983.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204931
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204933
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204935
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204937
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204939
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204941
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204943
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204945
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204947
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204949
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204951
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204953
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204955
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204957
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204959
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204961
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204963
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204965
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204967
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204969
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204971
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204973
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204975
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204977
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204979
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204981
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204983
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204985
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204987
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204989
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204991
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204993
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204995
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204997
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204999
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205001
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205003
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205005
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205007
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205009
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205011
Principal investigator 1 Emergent BioSolutions Inc. $1,070.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205013
Principal investigator 1 Emergent BioSolutions Inc. $1,070.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205015
Principal investigator 1 Emergent BioSolutions Inc. $798.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205017
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205019
Principal investigator 1 Emergent BioSolutions Inc. $798.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205021
Principal investigator 1 Emergent BioSolutions Inc. $798.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205023
Principal investigator 1 Emergent BioSolutions Inc. $798.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205025
Principal investigator 1 Emergent BioSolutions Inc. $798.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205027
Principal investigator 1 Emergent BioSolutions Inc. $798.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205029
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205031
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205033
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205035
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205037
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205039
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205041
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205043
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205045
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205047
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205049
Principal investigator 1 Emergent BioSolutions Inc. $733.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205051
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205053
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205055
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205057
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205059
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205061
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205063
Principal investigator 1 Emergent BioSolutions Inc. $226.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205065
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205067
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 02/03/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717205069
Principal investigator 1 PFIZER INC. $1,126.32 02/01/2020 Non-covered Recipient Entity
University Clinical Research DeLand LLC dba Accel Research Sites
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742934927
Principal investigator 1 PFIZER INC. $7,410.00 02/01/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978757
Principal investigator 1 PFIZER INC. $2,428.01 01/29/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900539
Principal investigator 1 Merck Sharp & Dohme Corporation $450.00 01/28/2020 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 740745351
Principal investigator 1 SANOFI PASTEUR INC. $7,700.00 01/28/2020 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744031407
Principal investigator 1 SANOFI PASTEUR INC. $13,250.00 01/23/2020 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744031393
Principal investigator 1 PFIZER INC. $4,137.26 01/22/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742900593
Principal investigator 1 PFIZER INC. $741.00 01/22/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978735
Principal investigator 1 PFIZER INC. $2,968.32 01/21/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900591
Principal investigator 1 Emergent BioSolutions Inc. $192.09 01/17/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204927
Principal investigator 1 PFIZER INC. $1,274.28 01/16/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978689
Principal investigator 1 PFIZER INC. $6,147.05 01/16/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742978693
Principal investigator 1 PFIZER INC. $821.50 01/15/2020 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742972651
Principal investigator 1 American Regent $5,700.00 01/13/2020 Non-covered Recipient Entity
University Clinical Rsearch - Deland, Llc
Heart_FID No dispute reported 06/30/2026 737106403
Principal investigator 1 Noven Pharmaceuticals, Inc. $150.00 01/10/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS (OA) OF THE KNEE. No dispute reported 06/30/2026 743838387
Principal investigator 1 Ferring Pharmaceuticals AS $16,016.00 01/09/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459543
Principal investigator 1 PFIZER INC. $11,331.13 01/08/2020 Non-covered Recipient Entity
Avail Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742978740
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 01/07/2020 Non-covered Recipient Entity
AVAIL CLNICAL RSRCH
Comparative study in Psoriasis No dispute reported 06/30/2026 749912645
Principal investigator 1 Boehringer Ingelheim International GmbH $1,300.00 01/07/2020 Non-covered Recipient Entity
AVAIL CLNICAL RSRCH
Comparative study in Psoriasis No dispute reported 06/30/2026 749912647
Principal investigator 1 Boehringer Ingelheim International GmbH $1,122.00 01/07/2020 Non-covered Recipient Entity
AVAIL CLNICAL RSRCH
Comparative study in Psoriasis No dispute reported 06/30/2026 749912649
Principal investigator 1 PFIZER INC. $1,624.64 01/07/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900541
Principal investigator 1 PFIZER INC. $9,927.54 01/04/2020 Non-covered Recipient Entity
University Clinical Research Deland LLC DBA Accel Research Sites
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900587
Principal investigator 1 Emergent BioSolutions Inc. $411.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204591
Principal investigator 1 Emergent BioSolutions Inc. $478.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204593
Principal investigator 1 Emergent BioSolutions Inc. $1,070.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204595
Principal investigator 1 Emergent BioSolutions Inc. $1,918.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204597
Principal investigator 1 Emergent BioSolutions Inc. $2,023.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204599
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204601
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204603
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204605
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204607
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204609
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204611
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204613
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204615
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204617
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204619
Principal investigator 1 Emergent BioSolutions Inc. $1,918.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204621
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204623
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204625
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204627
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204629
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204631
Principal investigator 1 Emergent BioSolutions Inc. $890.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204633
Principal investigator 1 Emergent BioSolutions Inc. $813.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204635
Principal investigator 1 Emergent BioSolutions Inc. $813.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204637
Principal investigator 1 Emergent BioSolutions Inc. $813.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204639
Principal investigator 1 Emergent BioSolutions Inc. $813.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204641
Principal investigator 1 Emergent BioSolutions Inc. $1,918.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204643
Principal investigator 1 Emergent BioSolutions Inc. $798.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204645
Principal investigator 1 Emergent BioSolutions Inc. $798.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204647
Principal investigator 1 Emergent BioSolutions Inc. $798.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204649
Principal investigator 1 Emergent BioSolutions Inc. $798.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204651
Principal investigator 1 Emergent BioSolutions Inc. $798.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204653
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204655
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204657
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204659
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204661
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204663
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204665
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204667
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204669
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204671
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204673
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204675
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204677
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204679
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204681
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204683
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204685
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204687
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204689
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204691
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204693
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204695
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204697
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204699
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204701
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204703
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204705
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204707
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204709
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204711
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204713
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204715
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204717
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204719
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204721
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204723
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204725
Principal investigator 1 Emergent BioSolutions Inc. $2,023.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204727
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204729
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204731
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204733
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204735
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204737
Principal investigator 1 Emergent BioSolutions Inc. $1,845.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204739
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204741
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204743
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204745
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204747
Principal investigator 1 Emergent BioSolutions Inc. $2,023.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204749
Principal investigator 1 Emergent BioSolutions Inc. $1,415.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204751
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204753
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204755
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204757
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204759
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204761
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204763
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204765
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204767
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204769
Principal investigator 1 Emergent BioSolutions Inc. $2,023.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204771
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204773
Principal investigator 1 Emergent BioSolutions Inc. $1,347.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204775
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204777
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204779
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204781
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204783
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204785
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204787
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204789
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204791
Principal investigator 1 Emergent BioSolutions Inc. $1,943.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204793
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204795
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204797
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204799
Principal investigator 1 Emergent BioSolutions Inc. $1,215.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204801
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204803
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204805
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204807
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204809
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204811
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204813
Principal investigator 1 Emergent BioSolutions Inc. $1,943.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204815
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204817
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204819
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204821
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204823
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204825
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204827
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204829
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204831
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204833
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204835
Principal investigator 1 Emergent BioSolutions Inc. $1,943.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204837
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204839
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204841
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204843
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204845
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204847
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204849
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204851
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204853
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204855
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204857
Principal investigator 1 Emergent BioSolutions Inc. $1,943.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204859
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204861
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204863
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204865
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204867
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204869
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204871
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204873
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204875
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204877
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204879
Principal investigator 1 Emergent BioSolutions Inc. $1,918.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204881
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204883
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204885
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204887
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204889
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204891
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204893
Principal investigator 1 Emergent BioSolutions Inc. $1,110.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204895
Principal investigator 1 Emergent BioSolutions Inc. $1,070.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204897
Principal investigator 1 Emergent BioSolutions Inc. $1,070.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204899
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204901
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204903
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204905
Principal investigator 1 Emergent BioSolutions Inc. $733.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204907
Principal investigator 1 Emergent BioSolutions Inc. $599.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204909
Principal investigator 1 Emergent BioSolutions Inc. $1,315.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204911
Principal investigator 1 Emergent BioSolutions Inc. $1,147.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204913
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204915
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204917
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204919
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204921
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204923
Principal investigator 1 Emergent BioSolutions Inc. $1,115.09 01/02/2020 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH -DELAND LLC
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study No dispute reported 06/30/2026 717204925